Clinical Trial

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2024 (before its estimated November 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in the few patients who never achieved an hematologic remission after whatever prior treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-07-14; most recent amendment 2024-10-21.
Status change: Recruiting → Active, Not Recruiting 2024-10-21
Status change: Not Yet Recruiting → Recruiting 2022-01-03
Trial Details
NCT Number NCT04475731
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
Enrollment 67 participants
Start Date 2021-05-04
Primary Completion 2024-11 (estimated)
Study Completion 2024-11 (estimated)
Updated on ClinicalTrials.gov 2024-10-22